Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma Case report

Main Article Content

Przemysław Będkowski
Wojciech Rogowski

Abstract

Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Będkowski P, Rogowski W. Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma. OncoReview [Internet]. 2021Jun.30 [cited 2024Mar.29];11(2(42):40-3. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1444
Section
PERSONALIZED ONCOLOGY

References

1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.02.2021).
2. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.
3. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4(suppl 2): e000818. http://doi.org/10.1136/esmoopen-2020-000818.
4. Charakterystyka produktu leczniczego INN-Paklitaxel.
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25. http://doi.org/10.1056/NEJMoa1011923.